Ticagrelor Tablet
Product Images NDC 72516-018

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 72516-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oryza Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure_1 (Figure 1)

This text provides data on patients treated with Tigomg and Clopidogrel, showing the number of events among patients and the Kaplan-Meier percentage at 12 months for each treatment group. The text also displays the days from the first study drug dose and the number of patients at risk over time.*

FDA Label Image

Fiigure_2 (Figure 2)

FDA Label Image

Chemical Structure (Chemical Structure)

FDA Label Image

Figure_8 (Figure 08)

This text appears to be a drug interaction recommendation guideline, providing information on the effects of ticagrelor (AR-C124910XX) when used in combination with different classes of drugs. It categorizes drugs as strong CYP3A4 inhibitors, moderate CYP3A inhibitors, potent CYP3A4 inducers, and P-gP and GYP3A inhibitors, giving recommendations on whether to avoid concomitant use, make dose adjustments, or use lower doses based on specific drugs. It also mentions certain drugs such as aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, and provides details on their administration and dose adjustments.*

FDA Label Image

Figure_10 (Figure 10)

This is a comparison between two treatments, clopidogrel and another medication, in patients with certain events over a period of 12 months. The text appears to show the results of a study in terms of the number of patients and events for each treatment group over different time points following randomization. The data seems to include days from randomization and the number of events at each time point for both medications.*

FDA Label Image

Figure_11 (Figure 11)

FDA Label Image

Figure_12 (Figure 12)

FDA Label Image

Figure_13 (Figure 13)

FDA Label Image

Figure_14 (Figure 14)

Available data includes HR (Hazard Ratio) with 95% CI (Confidence Interval) values for various factors, treatment effects comparison, and patient characteristics. The data provides insights into different subgroups based on characteristics such as age, weight, ethnicity, medical history, and treatment regimen. It also includes information on the usage of Ticagrelor compared to Placebo in a study involving patients with Coronary Artery Disease. The HR values indicate the relative risk of events occurring in the Ticagrelor group compared to the Placebo group. This data can be analyzed to understand the impact of different variables on outcomes and treatment efficacy.*

FDA Label Image

Figure_15 (Figure 15)

This is an evaluation of cumulative percentages of events over time in a clinical study. The data includes the number of events for each time point and the total number of patients at risk. The study involves the comparison of two treatments: one labeled "Nat risk" and the other "Ticagrelor." The timeline is measured in months from randomization. The information provided is essential for analyzing the efficacy and safety of these treatments in the study population.*

FDA Label Image

Figure_16 (Figure 16)

This text provides a detailed analysis of various factors affecting the treatment efficacy of Ticagrelor compared to a placebo in different groups of patients. It includes information on patient characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, and medical history including conditions like angina, diabetes, and smoking. The data presents Hazard Ratios (HR) with confidence intervals, showing how Ticagrelor performed compared to a placebo in different patient subgroups. These results are important for understanding the effectiveness of Ticagrelor in patients with different demographics and medical histories.*

FDA Label Image

Figure_17 (Figure 17)

The text provides data on the comparison between ticagrelor 90 mg twice per day and placebo in a clinical trial. The number of events for ticagrelor was 303 out of 5523 (5.4%) and for placebo, it was 362 out of 5493 (6.5%). The N values at risk for both groups are shown over time from randomization.*

FDA Label Image

Figure_18 (Figure 18)

This data provides information on a clinical trial's patient demographics, including age distribution, sex ratio, race, weight distribution, geographic regions, and medical history related to diagnoses such as stroke, TIA, diabetes, hypertension, prior ischemic events, smoking status, and cardiovascular conditions. The text also includes statistics comparing the efficacy of Ticagrelor versus Placebo in the study, measured by various health indicators.*

FDA Label Image

Figure_3 (Figure 3)

This data appears to show the number of participants at risk over time in a study evaluating the use of Ticagrelor (206/9562) versus Placebo (100/9531) in a certain event. The table shows the cumulative percentage over months from randomization. This information can provide insights into the progression of the study and the number of participants left at each time point.*

FDA Label Image

Figure_4 (Figure 4)

This data table shows the cumulative percentage of events for two groups receiving different treatments, Ticagrelor 90 mg and Placebo, in a study. The events are measured against the number of observed events and the total number of patients at risk. The table also provides the number of days from randomization for each group.*

FDA Label Image

Figure_5 (Figure 5)

FDA Label Image

Figure_6 (Figure 6)

FDA Label Image

Figure_7 (Figure 7)

This text provides information on the recommended dose adjustments for ticagrelor (AR-C124910XX) based on different intrinsic factors such as age, gender, ethnicity, renal impairment, hepatic impairment, and end-stage renal disease. It mentions that no dose adjustment is needed for most of the intrinsic factors considered. It also mentions specific conditions where ticagrelor has not been studied or where single doses should be administered with caution.*

FDA Label Image

Figure_9 (Image 09)

This text provides information about the interaction of Ticagrelor with various drugs. It lists different drugs along with their doses and whether any dose adjustment is recommended when used in combination with Ticagrelor. The text suggests the changes in effect and confidence intervals when Ticagrelor interacts with different drugs, such as Simvastatin, Amlodipine, Levonorgestrel, Estradiol, Torsemide, Digoxin, and Cyclosporine. It provides specific recommendations for dose adjustments based on the combination used.*

FDA Label Image

90 mg 60 Count Label (Image 90)

Each tablet contains 90 mg of ticagrelor. This medication is typically prescribed to adults, with dosage instructions available in the package insert. It is important to store the tablets in a safe place away from children and at a temperature between 20° to 25°C (68° to 77°F). This particular brand is distributed by Oryza Pharmaceuticals, Inc. and manufactured by Sunshine Lake Pharma Co., Ltd in Guangdong Province. Remember to provide each patient with the accompanying Medication Guide.*

FDA Label Image

Logo (Logo0001 01)

FDA Label Image

Logo0001-02 (Logo0001 02)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.